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Human diseases are caused by alleles that encompass the full range of variant types, from single-
nucleotide changes to copy-number variants, and these variations span a broad frequency spec-
trum, from the very rare to the common. The picture emerging from analysis of whole-genome
sequences, the 1000 Genomes Project pilot studies, and targeted genomic sequencing derived
from very large sample sizes reveals an abundance of rare and private variants. One implication
of this realization is that recent mutation may have a greater influence on disease susceptibility
or protection than is conferred by variations that arose in distant ancestors.Genetic Contributions to Disease
Common chronic diseases such as diabetes, coronary heart
disease, stroke, neuropsychiatric illness (including schizo-
phrenia, autism, and developmental disabilities), chronic respira-
tory disease, and cancer account for an overwhelmingly large
fraction of mortality, morbidity, and health care expenditure
(http://www.cdc.gov/nchs/). These diseases disproportionately
affect aging populations and burden the health care systems
and economies of industrialized nations throughout the world.
Understanding the underlying causes of such disorders is a
key step toward enabling earlier and more precise diagnosis,
prognosis, interventional therapy, and potentially prevention.
Most common diseases are complex ormultifactorial with both
environmental and genetic contributions along with their nearly
intractable interaction effects. In general, the environmental com-
ponents are challenging to identify and quantitate. In contrast, as
a result of the emergence of powerful genomic technologies, the
analysis of the genetic components is becoming increasingly
tractable and relatively inexpensive to investigate. These tech-
nical improvements have fueled a pipeline of discovery of the
genes and variants that predispose to humanmaladies. The tech-
nical improvements have also impacted genetic diagnostics, as it
is nowpractical to sequenceanentire individual’s genome for less
than the cost of a comprehensive set of whole-body imaging
scans. Furthermore, the cost of whole-genome sequencing is
rapidly becoming less expensive than current clinically imple-
mented ‘‘multigene panel testing’’ for molecular diagnosis of
disease traits with even modest genetic heterogeneity.
Allele Frequency Distributions and Human Disease
A ‘‘common disease/common variant’’ (CDCV) hypothesis has
been popularized as an explanation for common disorders and32 Cell 147, September 30, 2011 ª2011 Elsevier Inc.has garnered much support (Reich and Lander, 2001). This
model presupposes that different combinations of common
alleles aggregate in specific individuals to increase disease
risk. The CDCV hypothesis was a major intellectual impetus for
the International Haplotype Mapping (HapMap) project and ulti-
mately led to a proliferation of genome-wide association studies
(GWAS) identifying regions influencing disease status or risk
factor levels (http://www.genome.gov/gwastudies). As a conse-
quence, insights into potential newpathwaysunderlying common
disease have emerged.
Manolio et al. (2009) suggested that the genetic variance ex-
plained per se is of interest for what it might suggest about effec-
tive research paradigms. Accounting for the genetic variance is
not the same as achieving utility and impact. If the goal of
our shared research program is to achieve mechanistic under-
standing and lessen the impact of human disease, then the
magnitude of the genetic effect is less important than the
possible insight provided by the newly identified loci. Genes
identified through their weakly acting common alleles may give
important clues about pathways and/or be excellent targets for
therapeutic and preventive strategies.
However impressive the information gleaned from GWAS has
been, the results have explained only a few percent of the
apparent genetic variance contributing to common diseases.
Furthermore, these studies have not yet delivered medically
actionable variants that inform medical decision making by
helping to establish an etiological diagnosis and lead to a
more efficacious treatment or prevention plan. Both diagnostic
utility and classification of pathogenicity are closely associated
with the magnitude of each variant-specific effect. For most
complex diseases, unless a variant clearly partitions the affected
into distinct biological subgroups or can be incorporated into
risk-prediction models, there is likely to be limited diagnostic
usefulness. Morrison et al. (2007) proposed the use of a
composite ‘‘genetic risk score’’ for risk assessment. However,
it remains to be determined whether variants identified by
GWAS have a role as biomarkers in risk assessment and clinical
decision making. Overall, these data do not support a simple
additive version of the CDCV model as an explanation for the
majority of the genetic component underlying risk for common
disease.
Research efforts have shifted to exploration of less frequent
variants in common disorders. It has been noted for decades
that the mutational changes that underlie rare and highly pene-
trant Mendelian disease may share features with genetic factors
that underlie more common forms of the disease (Boerwinkle
and Utermann, 1988; Goldstein and Brown, 2001). Clearly, the
relationship between rare and common disease is not a simple
one, but there are emerging examples wherein specific loci
that cause ‘‘Mendelian disease’’ are contributing to the back-
ground risk to a parallel common disorder. Although a common
disease/rare variant (CDRV) hypothesis is attractive, it demands
tenable and complete explanations as to how the functional roles
of individual alleles can work to produce the ultimate phenotypic
effects. The models must consider the range of variant types,
including single-base or simple-nucleotide variants (SNV), short
insertions or deletions (indels), structural variants, and copy-
number variants (CNV), the penetrance of individual alleles, and
allelic and locus interactions (dominance and epistasis, respec-
tively) and showhow these all combine to produce the population
frequency and the phenotypic complexity of different disorders.
Fortunately, the current state of knowledge of key examples
supports models that close the gap between complex and
Mendelian traits. These examples show how mutations in single
genes can fulfill the definition of Mendelian disease—but in
different context are parts of the menu of causal contributors
to complex disorders (Greeley et al., 2010; Voight et al., 2010).
As we begin to observe instances wherein variation at more
than one locus contributes to perturbations of networks and ulti-
mate phenotype, the relevance of assessing genome-wide vari-
ation becomesmore apparent. Thus, inferences about individual
mutation burden by geneticists in the last century are now open
to direct observation (Muller, 1950).
Variation and Disease Susceptibility—We Are All Truly
Unique
The interplay between different types of variation and their
contribution to disease are highly dependent on our under-
standing of the normal patterns of genetic variation. For rare vari-
ants, this has been a particular challenge, as highly accurate
data need to be generated from many samples in order to prop-
erly determine the frequency and population distribution of the
genetic variants. To illustrate this: the successful HapMap
project (International HapMap 3 Consortium, 2010; International
HapMap Consortium, 2005; Frazer et al., 2007) that provided an
early survey of single-base variation across major human popu-
lations cataloged only a fraction of the genetic variation above
a frequency of 5%. Even the 1000 Genomes Project pilot studies
comprehensively captured only variation at greater than 1%
frequency (1000 Genomes Project Consortium, 2010).Our view of the site frequency spectrum of these rare variants
(<1%) has beenmore influenced recently as a result of the gener-
ation of personal genome data using whole-exome sequencing
and whole-genome sequencing (Gonzaga-Jauregui et al.,
2011). The number of diploid human genome sequences avail-
able for analyses is growing rapidly. Remarkably, from the small
number determined and publicly available to date, it is apparent
that even more genetic variation exists between individuals
than was previously expected (Ahn et al., 2009; Bentley et al.,
2008; Kim et al., 2009; Levy et al., 2007; Lupski et al., 2010;
Schuster et al., 2010; Wang et al., 2008; Wheeler et al., 2008).
When compared with the haploid reference, each individual
humangenomeon average contains some three andahalfmillion
SNV and about 1,000 CNV (>450 bp) (Conrad et al., 2010), many
of which appear to be rare in the population from which the indi-
vidual was sampled. In addition, each individual personal
genome sequence still reveals 200,000–500,000 SNV that have
not been observed in other publicly available personal genomes,
many of whichmay be unique to that individual’s family or clan. In
parallel, recent studies that deeply sequence relatively large
samples (hundreds to thousands of individuals) show that the
rate of identification of variants that have not been seen (private
variants) continues unabated with every new individual sampled
(Coventry et al., 2010; Turner et al., 2008). The extent of some of
this nucleotide variation may have been anticipated from human
genetic studies during the previous three decades that estab-
lished that an SNV occurs about every 1 Kb; however, the extent
of rare and ‘‘private’’ SNV was not anticipated, and the extent of
CNV was unexpected. There are technical limitations to some of
these studies—including a background of variation introduced in
cultured cells—as well as in the mutation detection methods
themselves, particularly for CNV in the 100 bp to 500 bp range,
low-copy repeat sequences, and simple repeats. Nevertheless,
the enormous extent of private variation has been clearly estab-
lished.
Rare Variants and New Mutation
A number of factors may have led to the observed skewing of the
allele frequency spectrum toward rare and private variants. The
explosion of human populations in the current historical epoch
could, by itself, account for the short branch lengths and low
frequencies of the most distal segments of human variant gene-
alogies (Boyko et al., 2008; Coventry et al., 2010; Turner et al.,
2008). In addition, secular factors that haveenabled theexplosion
of the population, such as abundant food supplies, improved
sanitation, and routine vaccinations, may directly participate in
the relaxation of the most important selective pressures that
have constrained the population in the past. Even thewidespread
availability of minimal routine health care may be artificially slow-
ingnegativeselection.Dramatic reductions inmaternal deathand
infant mortality, properly celebrated in the last 100 years, may be
influencing the distribution of genetic variation and contribute to
relaxed selection. Finally, mutation rate, perhaps partially driven
by increased paternal age (Crow, 2008) and undiscovered envi-
ronmental factors, may contribute to the observed rare variant
spectra.
The conceptual shift to emphasizing studies of abundant, rare,
and heterogeneous variants profoundly impacts our approachesCell 147, September 30, 2011 ª2011 Elsevier Inc. 33
to studying the genetic architecture of human disease, leading to
a genome-wide, versus a locus- or gene-specific, emphasis.
Genetic architecture here refers to the types of variation (SNV,
CNV, etc., both coding and noncoding), their allele frequency
distribution (common, rare, intermediate), the size of an allele’s
effects, and new mutation rates. For a given individual, what is
important to know is not only the number and location of patho-
genic variants taken one at a time but also the unique composi-
tion of his or her genome-wide mutational burden. If this is the
case, then the risk conferred by any particular allele estimated
from the population risk would be much less relevant than the
personal risk emerging from the total mutational burden in each
individual. The shift in emphasis to a whole-genome view
changes how we should consider the way in which harmful
combinations of mutant alleles assemble or accumulate in each
genome. Each personal genome has a collection or ‘‘ecology’’
of deleterious and protective variations, which in combination
(not necessarily in sum) dictate the health of the individual.
Understanding this genome ecology will be a substantial chal-
lenge in human genetics and has ramifications for the extent to
which genetic information can be maximized for medical utility.
Each personal genome combines inherited alleles and new
variation introduced by de novo mutation. Interestingly, CNV
may contribute in a significant way, from both the novel combi-
nations inherited from each parent and the new mutations. This
is the very type of variation not fully taken into account when
previous mutation models were being considered. Locus-
specific mutation rates for SNV are 2.0–2.5 3 108 and have
recently been shown to potentially differ in male versus female
germ cells (Conrad et al., 2011); for CNV, new mutation rates
can be substantially higher: between 106 and 104, 100 to
10,000 times more frequent than in SNV (Lupski, 2007a). The
latter figures implicate CNV in sporadic traits (Lupski, 2007a)
including birth defects (Lu et al., 2008) and highlight the contribu-
tion of new mutation to individual mutational burden (Potocki
et al., 1999). Either new or recent (i.e., arising in close relatives
or ‘‘clan members’’) de novo mutations could substantially
contribute to phenotypic extremes, such as birth defects and
disease.
Although de novo CNV have been detectable now for some
time with microarray technologies, identifying smaller de novo
events (e.g., SNV) has become feasible only recently with the
advent of large-scale DNA sequencing technologies. Recent
exome sequencing studies of family trios with patients manifest-
ing sporadic intellectual disability (previously more frequently
referred to asmental retardation [MR]) identified a high frequency
of de novo mutations in ‘‘MR genes’’ (Vissers et al., 2010). Such
studies support established theory that if the mutational target
is large (and hence the observed gene mutation rate is high), de
novo mutations may account for a high incidence of disease
even when the selection coefficient is close to 1.0. These early
studies suggest a resolution to the question of why the frequency
of neurodevelopmental disabilities is high despite near genetic
lethality for such traits. Relatedly, sequencing studies of multiple
ion channel genes in patients with epilepsy (Klassen et al., 2011)
and of known autism susceptibility genes in subjects with high-
functioning autism (Schaaf et al., 2011) reveal many rare variants
and also de novo mutations that may be contributing to disease.34 Cell 147, September 30, 2011 ª2011 Elsevier Inc.The concept of new mutation in X-linked lethal disorders was
well established by Haldane (Haldane, 1935). However, the new
mutation contribution to many human disease traits may be
greater than anticipated (Hoischen et al., 2010), particularly for
genetically heterogeneous conditions in which hundreds of
genes could be involved but only one or a few loci are responsible
in an individual patient. The developmental timing of new somatic
mutations is perhaps underappreciated (Lupski, 2010) as
previous studies have emphasized germline events. New muta-
tionsmay occur in the germline, during any stage of development
of the organism, in stem cells, or in differentiated somatic cells.
Chromothripsis in cancer (Stephens et al., 2011) and complex
genomic rearrangements (CGR) associated with selected
genomic disorders (Liu et al., 2011) both illustrate the potential
gene(s) alteration—complexities that can be brought about by
new mutation CNV events. In each case, a single mutational
event can result in a cataclysmic chromosomal catastrophe
and alter the copy number or structure of several different genes.
‘‘Clan Genomics’’
Most sites of variation have low minor allele frequencies (that is,
are rare) and are of recent origin, and therefore themajor contrib-
utors to inherited disease susceptibility are likely to be those
alleles that arose recently in an extended pedigree. Purifying
natural selection is expected to eliminate highly deleterious vari-
ants before they reach a high frequency, such that disease risk
alleles with large effects should be enriched at the lower frequen-
cies (Marth et al., 2011). The idea that there are unique combina-
tions of rare variants characteristic of a recent family lineage and
that these combinations can have a causative role in disease is
encapsulated by what we refer to as ‘‘clan genomics’’ (Figure 1).
The population from which one comes and its collection of older
common variants may have less influence on an individual’s
disease susceptibility than the collection of recently arisen rare
variants and de novo mutations (Figures 2A and 2B). The most
important thing that an individual needs to consider in terms of
their genetic variation with relation to disease susceptibility is
therefore recent ‘‘genetic history’’ of their extended pedigree or
clan. From the standpoint of delivering personalized genomic
medicine, the medically actionable alleles are the ones of most
interest; and these may be highly weighted toward recent rare
variants.
Nevertheless, the most important thing is not to focus dispro-
portionately on specific variants, but rather to integrate across all
classes of risk-associated variants. In some individuals, risk may
be caused by an unusual combination of common variants,
whereas in others it will be due to a smaller number of large effect
rare variants.
Mendelian Disease and Complex Traits
Resequencing studies of genes that can cause rare Mendelian
forms of common complex traits reveal that rare variants can
contribute to hypertension (Ji et al., 2008; Wagner, 2008), hyper-
cholesterolemia (Kotowski et al., 2006), hypertriglyceridemia
(Romeo et al., 2009), and nonalcoholic fatty liver disease (Romeo
et al., 2008) in the population at large. These examples inform
models where individual alleles with high penetrance contribute
to common complex traits. In addition, when GWAS signals
Figure 1. Clan Genomics
Heat map and extended pedigree showing the conceptual relationship among
de novo mutations leading to disease (red), recent mutations with moderate
effects arisingwithin a clan (yellow and green), and older common variantswith
small effects segregating in the population (blue). An individual’s genetic
disease risk emerges from the collection of variants he or she has inherited
from both parental lineages of distant ancestors (typically common and of
individually small effect), more recent ancestors (rare, but potentially larger
effect), and de novo mutations.have identified variants for common traits, their molecular
mechanistic underpinnings often support those already estab-
lished by Mendelian forms of the condition (Sankaran et al.,
2008, 2009; Vernimmen et al., 2009).
The idea that genes responsible for Mendelian disease can
also have a role in the common form of the same or a similar
condition is not new. For example, the pioneering studies of
Michael Brown and Joseph Goldstein showed that individuals
with compound heterozygous mutations in the low-density
lipoprotein receptor (LDLR) gene manifest the Mendelian
disorder familial hypercholesterolemia (FH) (Brown and Gold-
stein, 1986; Goldstein and Brown, 1987). FH patients have
extremely high cholesterol levels and can have coronary athero-
sclerotic heart disease and myocardial infarctions in their
teenage years. Interestingly, the type of LDLR gene mutation
predicts cardiovascular risk in children with familial hypercholes-
terolemia (Guardamagna et al., 2009). Heterozygous rare variant
mutations at the LDLR locus can also cause the complex traits
of early onset hypercholesterolemia, coronary atherosclerotic
heart disease, andmyocardial infarctions in carriers with disease
manifesting in the fourth or fifth decades of life.
Recessive Mendelian Mutations Can Increase Complex
Disease Risk in Carriers
Heterozygous carriers for recessive disease genes do not mani-
fest the recessive disease but may be susceptible to a milder or
related malady, which may consist of a complex trait with
a similar phenotype. For example, heterozygote carriers of muta-
tions in the ataxia telangiestasia locus are susceptible to breastcancer (Athma et al., 1996), and similar heterozygous carrier
susceptibilities are also manifest for other recessive human
cancer predisposition syndromes (Heim et al., 1991). Carriers
for mutations in the Gaucher disease causative gene, GBA en-
coding glucocerebrosidase, are at increased risk for Parkinson
disease (Goker-Alpan et al., 2004; Sidransky et al., 2009). Hetero-
zygous carriers of mutations in the cystic fibrosis transmembrane
regulator gene, CFTR, can be susceptible to idiopathic pancrea-
titis (Cohn et al., 1998; Sharer et al., 1998; Weiss et al., 2005),
chronic obstructive pulmonary disease (COPD) (Divac et al.,
2004), and even chronic rhinosinusitis (Wang et al., 2000, 2005).
Carriers of a-1-antitrypsin (AAT) deficiency can also be suscep-
tible to COPD (Hersh et al., 2004; Poller et al., 1990). Interestingly,
even such common traits as age-related macular degeneration
(AMD) and carpal tunnel syndrome are associated with hetero-
zygous carrier status for mutations in ABCA4, the gene respon-
sible for Stargardt macular dystrophy (Bacq et al., 2009), and
Charcot-Marie-Tooth neuropathy genes (Lupski et al., 2010),
respectively (Figures 2C and 2D). In the latter case, haploinsuffi-
ciency due to either heterozygous SNV (Lupski et al., 2010) or
heterozygous CNV (Del Colle et al., 2003) can convey the trait.
Whereas most carrier states may have rare allele frequencies,
otherswill actually have a significant carrier frequency in selected
populations (e.g., CFTR 4% in European descendants).
Genes and Single Loci Implicated in Mendelian Disease
and in Complex Disease Risk
In addition to variants that cause Mendelian disease-informing
complex traits, there is a striking reciprocity of genes implicated
by GWAS that are also known to underlie rare Mendelian
diseases. For example, 11 of 30 genes associated with serum
lipid levels are implicated in single-gene disorders of lipidmetab-
olism (Kathiresan et al., 2009). We reviewed the current listing of
annotated genes with significant associations in 891 GWAS
studies (http://www.genome.gov/gwastudies/). We found that
at least 268 genes implicated by GWAS are also known to bear
mutations in rare single-gene disorders. Some of these associa-
tions are intuitive, such as those associated with biochemical
traits and related inborn errors of metabolism. There are also
a significant number of genes that underlie developmental disor-
ders that harbor common variants affecting risk of cancer, body
growth, and cardiovascular traits (Table S1 available online). This
raises the testable hypothesis that genetic influences on human
diseases can largely be accounted for by a subset of genes that
play roles in a restricted set of pathways. Immune and inflamma-
tory pathways provide a robust example as do those genes
involved in lipid metabolism. It is important to note that in our
survey, for most cases of GWAS the causal gene underlying
a given GWAS signal is unknown.
Whereas GWAS can indirectly implicate ‘‘Mendelian genes’’ in
complex disease risk, different mutations of a single gene, or
a CNV at a single locus, are directly implicated in complex
disease risk. A poignant example of the different phenotypic
consequences of distinct allelic variants at a locus is provided
by the fragile X mental retardation 1 (FMR1) locus. Triplet repeat
expansion of the CGG repeat element in the 50 untranslated
region (UTR) of the FMR1 gene—an especially unstable form of
indel mutation—causes severe X-linked mental retardation in
both males and females. Alleles with lower numbers of CGGCell 147, September 30, 2011 ª2011 Elsevier Inc. 35
Figure 2. Phenotypic Consequences of Allele Combinations
This figure demonstrates ‘‘clan genomics,’’ wherein the combinations of alleles one inherits from his or her nearest relatives profoundly affect clinical outcome. In
these illustrative pedigrees, different combinations of ABCA4 alleles can affect age-of-onset of Stargardt macular dystrophy (STGD; MIM 601691) (A), Mendelian
versusmultifactorial trait (i.e., Stargardt disease versus age-relatedmacular degeneration [AMD]) (B), or retinal disease type (i.e., Stargardt disease versus retinitis
pigmentosa [RP; MIM 601718]) (C).
(D) Differing SH3TC2 alleles result in recessive Charcot-Marie-Tooth disease (CMT; MIM 601596), dominant axonal neuropathy, or the complex trait of carpal
tunnel syndrome.repeats (55–200 repeats; called premutation alleles), however,
cause adult onset tremor/ataxia syndrome (FXTAS) in approxi-
mately 33% of males and 10% of females (Hagerman et al.,
2004; Jacquemont et al., 2004). Thus, premutation variants
that have been considered nonpathogenic can have phenotypic
consequences for common complex traits such as tremor and
ataxia.
Rare CNV at different loci have also recently been associated
with complex traits including Alzheimer disease (Rovelet-Lecrux
et al., 2006), Parkinson disease (Farrer et al., 2004; Singleton
et al., 2003), lupus glomerulonephritis (Aitman et al., 2006), Crohn
disease (Fellermann et al., 2003, 2006; McCarroll et al., 2008),
psoriasis (Hollox et al., 2008), pancreatitis (Le Mare´chal et al.,
2006), and obesity (Bochukova et al., 2010). Many rare CNV
have also been associated with intellectual disability (Stankie-
wicz and Beaudet, 2007) and with some forms of neuropsychi-
atric illness, including schizophrenia (Consortium, 2008; Lupski,
2008; McCarthy et al., 2009; Stefansson et al., 2008) and autism
(Kumar et al., 2008; Shinawi et al., 2010; Weiss et al., 2008).
Same Gene, Different Mutations, Diseases,
and Modes of Inheritance
A further illustrative example of the connection between Mende-
lian and complex traits is provided by variants at the MECP236 Cell 147, September 30, 2011 ª2011 Elsevier Inc.locus and their contribution to disease. Heterozygous loss-of-
function SNV in MECP2 result in the X-linked dominant trait of
Rett Syndrome in girls (Amir et al., 1999); however, hemizygous
loss-of-function mutations are thought to be lethal in males.
Recently, duplication of CNV includingMECP2 has been associ-
ated with an intellectual disability plus seizure disorder in males
(Carvalho et al., 2009; del Gaudio et al., 2006; Friez et al., 2006;
Meins et al., 2005; Van Esch et al., 2005) and autism spectrum
disorder (Ramocki et al., 2009; Schaaf et al., 2011). Male patients
with triplication of MECP2 have a more severe phenotype (del
Gaudio et al., 2006). Of note, maternal carriers of the MECP2
duplication (CNV) appear more susceptible to psychiatric symp-
toms unrelated to having a child with a disability (Ramocki et al.,
2009). Thus, at a single locus, the genetic variation can cause an
X-linked dominant disorder in females and an X-linked recessive
trait in males and can be associated with susceptibility to
a common complex trait in carrier mothers.
For mutations at a single locus, allelic interactions can
profoundly affect clinical phenotype. At the ABCA4 locus, the
disease severity is related to the residual activity of encoded
transporter protein (Figures 2A–2C). Recessive Stargardt dis-
ease is caused by compound heterozygous mutations at this
locus (Allikmets et al., 1997b). Homozygous or compound
Figure 3. Models of Disease Allele Transmission
(A) In classical Mendelian disease, for a recessive, monogenic disease, at that
single locus there is biallelic inheritance (highlighted in box). Examples could
be either Stargardt macular dystrophy or cystic fibrosis, which are both due to
point mutations in ATP-binding cassette (ABC) transporter genes. However, at
some loci in the human genome, imprinting results in monoallelic expression,
and the disease phenotype will occur in a manner dependent on the parent of
origin of the specific mutation, either by deletion copy number variants (CNV)
or uniparental disomy (UPD). The example given is the Angelman syndrome
with point mutations in theUBE3A gene. TheCMT1A locus (17p12) represents
a triallelic locus whereby because of the duplication, there are three copies of
the PMP22 gene. None of the copies have point mutations in them, but it takes
three copies to convey the clinical phenotype. Other examples of disease allele
transmission include interactions between two or potentially more genes. In
the classic model of digenic inheritance, the phenotype of retinitis pigmentosa
has been shown to be due to heterozygous point mutations in the ROM1 gene
in combination with heterozygous point mutations at the RDS locus. Thus
there is biallelic digenic inheritance. Note that a genomic deletion CNV renders
a locus monoallelic, whereas a duplication CNV results in a triallelic locus.
(B) Bardet-Biedl syndrome (BBS), traditionally thought of as a recessive trait,
can sometimes result from three mutant alleles, two of which come from one
locus, and one from another locus. This is an example of digenic triallelic
inheritance.
(C) A single pedigree illustrates triallelic inheritance for BBS. Standard pedi-
gree symbols are used; filled squares, affected with BBS. Alleles segregating
at two distinct loci (BBS2 and BBS6) are shown, one in each pedigree. WT,
wild-type or normal allele.
Figure 4. Totality of Pathogenic Variants, Disease Severity, and Clan
Genomics
Pedigrees of families segregating Charcot-Marie-Tooth (CMT) neuropathy,
illustrating that disease severity is directly related to pathogenic mutational
burden.
(A–C) Mutations at two different CMT loci result in a more severe phenotype.
These double heterozygotes may be due to either a single-nucleotide variant
(SNV) + copy-number variant (CNV) (A and B) or two SNV (C) (Chung et al.,
2005; Hodapp et al., 2006; Meggouh et al., 2005).
(D) In a single family, disease results from homozygousMTMR2mutation (likely
related to consanguinity) or de novo CNV—the CMT1A duplication (PMP22)
(Verny et al., 2004); an example of clan genomics.heterozygous mutations, if both null, result in retinitis pigmen-
tosa. Within a single pedigree or clan, different combinations of
alleles can result in differing ages of onset (Lewis et al., 1999),
completely different diseases (Shroyer et al., 2001a), or both
a recessive Stargardt disease and susceptibility to a complex
trait, age-related macular degeneration, due to a heterozygous
carrier state (Figure 2) (Shroyer et al., 1999, 2001b).Multiple Mutated Genes Underlying Clinical Phenotypes
Rare point mutations (either functional noncoding SNV [Kurotaki
et al., 2005] or coding SNV with incomplete penetrance [Shy
et al., 2006]) in combination with a deletion CNV have been
shown to contribute together to particular phenotypes. A com-
bination of a rare deletion CNV with a de novo duplication CNV
can also result in a phenotype that appears to be a complex trait
(Potocki et al., 1999). Sometimes SNV mutations at two different
loci, i.e., digenic inheritance, are required to manifest a trait
segregating as a recessive disease, and the mutational load
required may have a single mutant allele at each of the two loci
(Kajiwara et al., 1994) (double heterozygous) or twomutant alleles
at one locus and one at the other (triallelic inheritance) (Figure 3)
(Katsanis et al., 2001). With respect to models for Mendelian
transmission, a deletion CNV renders a locus monoallelic,
whereas a duplication CNV results in a triallelic locus (Figure 3).
It is nowwell established that even simpleMendelian traits can
have modifier loci (Badano and Katsanis, 2002; Dipple and
McCabe, 2000), demonstrating the potential importance of
nonhomologous allelic interaction and epistasis. For example,
severity of disease for CMT can be due to a combination ofmuta-
tions at more than one CMT locus (Chung et al., 2005; Hodapp
et al., 2006; Meggouh et al., 2005) (Figures 4A–4C).Cell 147, September 30, 2011 ª2011 Elsevier Inc. 37
Figure 5. Bridging the Gap between Chro-
mosomal Syndromes and Mendelian Disor-
ders
(A) Chromosomal duplication mapping wherein
chromosomally visible duplication abnormalities,
as evidenced by altered G-banding patterns, are
used to delineate the portion of the genome re-
sponsible for the reduced motor nerve conduction
velocities that accompany the demyelinating form
of Charcot-Marie-Tooth disease (CMT1A; MIM
118220). Several different chromosomal abnor-
malities have been reported in association with
a CMT1 phenotype. Note, different chromosome
17 abnormalities including direct duplications, in-
verted duplications, and inherited as well as de
novo translocations have been reported with
complex phenotypes that include CMT. If the
duplicated genomic interval encompasses the
17p12 dark G-band where the PMP22 gene maps
(*), then the patient will have a demyelinating
neuropathy, as evidenced by decreased motor
nerve conduction velocities, as part of their clinical
phenotype.
(B) Submicroscopic genomic rearrangements
associated with neuropathy. Vertical lines repre-
sent a ‘‘blow-up’’ of the genomic interval within
17p12 containing the PMP22 gene (filled rect-
angle). The horizontal parentheses delimit the
rearranged interval for the common deletion
(depicted by absence of vertical line) and dupli-
cation (two copies of gene and interval). To the
right are rare-sized copy-number variants (CNV) depicting genomic deletion (green dots on array CGH) versus duplication (red dots on array).
(C) shows genotype/phenotype correlations between PMP22 point mutations associated with neuropathy. The T118M missense amino acid substitution in
PMP22 appears to be a reduced penetrance loss-of-function allele. As a heterozygous mutation it can result in a mild hereditary neuropathy with liability to
pressure palsies (HNPP) phenotype in some individuals; as a homozygous allele it can convey a severe axonal neuropathy. Interestingly, when the T118M allele
occurs in combination with the HNPP deletion, a severe demyelinating phenotype results. Of further interest, when the T118M allele occurs in combination with
the CMT1A duplication, the loss-of-function missense amino substitution appears to mitigate some of the consequences of the gain-of-function duplication
CNV.Large CNV or Aneuploidy Can Simultaneously
Affect Multiple Genes
In contrast to the trans-genetics of Mendelism (Figures 2–4),
genetic interactions occurring on the same chromosome or in
cis (Figures 5A–5B) can also have profound consequences as
exemplified at the alpha globin locus. For structural variants,
the genomic mutational load can reflect the size of the CNV
and inclusion of additional dosage-sensitive genes or genomic
segments in cis (Bi et al., 2009; Lupski et al., 1991, 1992; Roa
et al., 1996). Two extreme examples of this ‘‘cis-genetics’’ effect
are segmental aneuploidy (Figure 5) and complete aneuploidy
(e.g., trisomy 21) that convey complex phenotypes related to
the size of the CNV and number of dosage-sensitive genes
and/or genomic segments involved. For Down syndrome associ-
ated with trisomy 21, this includes an endophenotype of early
onset Alzheimer disease; the amyloid precursor protein (APP)
gene maps to chromosome 21, and duplications involving this
gene have indeed been associated with Alzheimer disease
(Rovelet-Lecrux et al., 2006).
For intellectual disability, recent studies suggest the possibility
that two independent CNV (El-Hattab et al., 2010; Girirajan et al.,
2010; Potocki et al., 1999) can contribute to the ultimate pheno-
type, as shown in individual patients and as predicted by
previous models (Lupski, 2007b).
In aggregate these data show that rare variants and the
genome-wide totality of pathogenic alleles contribute to com-
plex traits (Allikmets, 2000; Allikmets et al., 1997a; Douros38 Cell 147, September 30, 2011 ª2011 Elsevier Inc.et al., 2008; Hersh et al., 2004; Lupski, 2007b; Poller et al.,
1990; Wittrup et al., 1997, 2006). Unfortunately, such rare vari-
ants are not being accounted for in many current GWAS, and
CNV and noncoding SNV are not detected by typical whole-
exome sequencing approaches.
A Unified Genetic Model for Human Disease
In the past, focused, locus-specific, single-gene analyses have
elucidated genetic etiologies for disease, but it is now emerging
that whole-genome sequencing will produce a more complete
assessment of genetic variation contributing to personal health.
The genome of each individual contains the inherited contribu-
tion of common variants that segregate within the population,
the inherited contributions of rare variants that emerged in recent
history in the clan, the new combinations of such recently arising
variants from both parents, and the new mutation contributions
yielding the total mutational burden (Figure 1). Highly penetrant
rare variants, and often de novo mutations, contribute medically
actionable alleles toMendelian disease and perhaps extremes of
phenotypes in common disease. Common variants can con-
tribute to medically actionable variants for pharmacogenomics
traits.
What emerges is a unified picture whereby previously distinct
entities or categories of human diseases, chromosomal syn-
dromes, genomic disorders, Mendelian traits, and common
diseases or complex traits, can now be considered as part of
one continuum (Figure 6), whereby common and rare variants
Figure 6. A Continuum for the Genetics of Human Disease
The square (center) represents genomic variation that can influence the
different categories of genetic disease. The circles represent the overlapping
categories of human disease with darker regions depicting intersection with
greater overlap in the underlying genetic influences on these given disease
categories. A unified model for human genetic disease proposes that all major
categories of disease with genetic influence—Mendelian disease, common
disease or complex traits, genomic disorders, and chromosomal syndromes—
can be explained by variation in DNA sequence (SNV) or copy number (CNV)
from a ‘‘wild-type’’ diploid state. Whereas trans-genetic interactions at a single
locus (alleles) or between loci may contribute to Mendelian disease and
complex traits, cis-genetic interactions can be important to phenotypic
manifestations in genomic disorders (CNV) and chromosomal syndromes
(segmental aneuploidy). Digenic and triallelic inheritance bridge Mendelian
traits and complex disease; each represents an oligogenic inheritance model.including de novo mutations in the context of environmental
influences result in perturbation of the biological balance of
a restricted set of networks activating final common pathways
that ultimately cause disease. Even though there may be many
loci that contribute to interindividual inherited susceptibility of
a phenotype in a population, in any one individual rare or com-
mon variants from just a few may be responsible for the trait
(i.e., oligogenic inheritance). Extreme genetic heterogeneity
and the contributions of new mutation may underlie some of
the apparent complexity of complex traits.
A unified genetic model for human disease breaks down the
artificial boundaries between categories of human disease
(Figure 6). It views all human disease categories including com-
plex traits, Mendelian disease, genomic disorders, and even
chromosomal syndromes as representing a spectrum of pheno-
typic manifestations reflecting the totality of pathogenic variants:
ancestral alleles, those arising in recent ancestors (clan), unique
combinations inherited from parents, and de novo variants
(Figure 1). A full accounting of individual mutational load
genome-wide and expansion of the current genocentric, locus-
specific model opens the door to reinvestigation of classic
problems in human genetics. These challenges include under-
standing the molecular basis of incomplete penetrance and vari-
able expressivity of monogenic traits, clinical manifestations of
‘‘recessive alleles’’ (i.e., weak semidominance), homologous
allelic interaction and nonhomologous allelic interaction, and
their effects on disease and health. This new synthesis is
required to interpret the ecology of individual genomes in thecontext of complete individual genetic variation data, population
genetics, and evolution.
Genome-wide assays including whole-genome sequencing,
copy-number arrays, and transcriptional profiling are among
the current technologies that can be used to further explore
and test the ‘‘genome-wide totality of pathogenic variants’’
hypothesis. These genome analysis methods can now generate
a massive data flow, opening up to experimental exploration
fundamental questions that have occupied the minds of genera-
tions of scientists and philosophers. Yet, such genome-wide
experimental assays alone will be insufficient. Other challenges
include: How many types of variants (repeat expansions, CNV
between 100 and 500 bp, etc.) are we missing with current
techniques? How will we validate the phenotypic effects of vari-
ants observed in a single individual or family? What analytical
approaches should clinical genome sequencing projects adopt
given the sheer complexity of some of the gene-disease associ-
ations described herein? How can we integrate disease risk
emerging from common and rare variants in an individual
genome? Can disease phenotypes be refined and redefined by
molecular correlates such as gene expression, chromatin
conformation, DNA methylation, and all of the other ‘omics?
Can individual serial observation of molecular phenotypes,
much as we currently do for routine lab measures such as
glucose and lipids, show us stronger effects of underlying
genetic variation that are otherwise poorly captured by cross-
sectional studies and lead us to yet new models?
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